Vitrectomy with Internal Limiting Membrane Peeling with Intravitreal Ranibizumab Injection for Patients with Central retinal Vein Occlusion with Combined Epiretinal Membrane

Abstract

Background: Central retinal vein occlusion (CRVO) is one of the most common causes of visual loss in general population especially in middle age and elderly people. Aim of The Work:To assess the role of vitrectomy with internal limiting membrane (ILM) peeling with intravitreal ranibizumab injection for patients with CRVO with combined epiretinal membrane (ERM). Patient and Methods:The study was conducted on eleven patients with CRVO with coexisting ERM. Best corrected visual acuity (BCVA) converted into logMAR, fundus Fluorescein angiography and optical coherence tomography (OCT) assessing central macular thickness (CMT) were done. All patients had undergone vitrectomy with ILM peeling with intravitreal injection of ranibiaumab (0.5 mg/0.05 ml). Postoperatively, the patients were examined 1 week and 1 month for BCVA in logMAR and full ophthalmic examination. Also, OCT was done one month postoperatively. Results: There was a significant decrease in one week (1.064±0.258) and four weeks (0.718±0.316) postoperative BCVA in log Mar than preoperative BCVA (1.245±0.221). Also, there was a significant reduction in the four-week postoperative CMT (357.73±133.094) than preoperative CMT (497.27±225.420) ( =0.003). Conclusion:Vitrectomy combined with ILM peeling with intravitreal ranibizumab injection showed anatomical efficacy for macular edema (ME) in eyes with CRVO associated with ERM. Also, BCVA improved significantly concurrently.